03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *
Kidrolase* : | |
Type | Medicine Non Marketed |
Originator | Biotech (Kidrolase) |
Agent | Droguerie de l'Union |
Distributor | Droguerie de l'Union |
Laboratory | Jazz Pharmaceuticals |
Responsible Party | Jazz Pharmaceuticals France SAS |
Origin | France |
Manufacturer | Cenexi - Laboratoire Thissen |
Origin | Belgium |
ATC | L01XX02 |
Kidrolase* :
Kidrolase* :
Kidrolase* :
Kidrolase* :
Kidrolase* :
Hazard Level |
---|
◼ Major |
◼ Moderate |
◼ Minor |
◼ Safe |
Kidrolase* :
Kidrolase* :
Frequency | Percentage |
---|---|
Very Common | ≥ 1/10 |
Common | ≥ 1/100 - < 1/10 |
Uncommon | ≥ 1/1,000 - < 1/100 |
Rare | ≥ 1/10,000 - < 1/1,000 |
Very Rare | < 1/10,000 |
Unknown | Cannot be Estimated |
Effect | Frequency |
---|---|
Abdominal pain | Common |
Activated partial thromboplastin time prolonged | Very Common |
ALT increased | Common |
Amenorrhoea (amenorrhea) | Not known |
Anaemia | Not known |
Anaphylactic reactions | Very Common |
Anaphylactic shock | Not known |
Antithrombin III decreased | Very Common |
Arterial thrombotic events | Common |
AST increased | Common |
Azoospermia | Not known |
Blood bilirubin increased | Common |
Bone marrow failure (Myelosuppression) | Not known |
Bronchospasm | Very Common |
Chills | Common |
Coagulation disorders | Very Common |
Coagulation factor IX level abnormal | Very Common |
Coagulation factor VII level abnormal | Very Common |
Coagulation factor VIII level abnormal | Very Common |
Coagulation factor X level abnormal | Very Common |
Coma | Not known |
Confusional state | Not known |
Cytolytic hepatitis | Not known |
Diabetic ketoacidosis | Not known |
Diarrhoea (Diarrhea) | Common |
Dyspnoea (dyspnea) | Very Common |
Erythema | Very Common |
Face oedema | Very Common |
Fatigue | Not known |
Febrile neutropenia (Neutropenic fever) | Not known |
Fever | Common |
Fibrinogen decreased | Very Common |
Flushing | Not known |
Gamma-GT increased | Common |
Haemorrhage | Not known |
Hepatic failure (Hepatic insufficiency) (Liver failure) | Rare |
Hepatic steatosis | Not known |
Hepatitis cholestatic | Not known |
Hepatomegaly | Not known |
Hyperammonaemia | Not known |
Hyperamylasaemia | Common |
Hypercholesterolaemia | Not known |
Hyperglycaemia | Common |
Hyperinsulinism | Common |
Hypertension | Not known |
Hypertriglyceridaemia | Common |
Hypoalbuminaemia | Not known |
Hypotension | Very Common |
Infection | Not known |
Injection site erythema | Not known |
Injection site haematoma | Not known |
Injection site oedema | Not known |
Injection site pain | Not known |
Laryngeal oedema | Very Common |
Leucopenia (Leukopenia) | Not known |
Lip swelling | Very Common |
Lipase increased | Common |
Malaise | Not known |
Metabolic encephalopathy | Not known |
Myocardial infarction | Not known |
Nausea | Very Common |
Necrotizing pancreatitis | Very rare |
Neutropenia | Not known |
Oedema peripheral | Common |
Pain | Common |
Pancreatitis | Not known |
Pancreatitis acute | Common |
Pancreatitis haemorrhagic | Very rare |
Phosphatase alkaline increased | Common |
Plasminogen decreased | Very Common |
Posterior reversible leukoencephalopathy syndrome (PRES) | Rare |
Protein C decreased | Very Common |
Protein S decreased | Very Common |
Prothrombin time prolonged | Very Common |
Pruritus | Very Common |
Renal insufficiency | Not known |
Sepsis (Systemic infection) (Sepsis state) | Not known |
Stupor | Not known |
Thrombocytopenia (Thrombopenia) | Not known |
Urticaria | Very Common |
Venous thromboembolic event | Common |
Vomiting | Very Common |
Kidrolase* :
NB : Products With Same Indication |
Different Units By MoH Code
Kidrolase* MoH 1792 :
Form | Powder for solution for injection |
Packaging | Vial (Type II Glass) + Ampoule (Type I Glass) |
Package Size | 10+10 |
Strength | 10000IU |
NSSF | ✘ |
Quarantine | ✔ |
Reg. Number | 26643 |
Submission date | 01/01/1989 |
Registration Year | 1989 |
Archived Date | 08/04/2022 |
Price Comparison
You have to register to view this info
You have to register to view this info
You have to register to view this info
You have to register to view this info
You have to register to view this info
Note
You have to register to view this info
Drop File